ПАЦИЕНТ С МЕРЦАТЕЛЬНОЙ АРИТМИЕЙ НА АМБУЛАТОРНОМ ПРИЁМЕ У ТЕРАПЕВТА

Clinical observation of outpatients and deceased patients with atrial fibrillation, as well as implementing the Recommendations of the Russian Society of Cardiology and the European Society of Cardiology for the management of patients with atrial fibrillation were discussed during Moscow district therapists’ conference and online broadcast. All participants in the interactive format considered prevention of thrombotic events (such as strokes) by means of modern antithrombotic therapy using novel oral anticoagulants.

1. Angeli F., Reboldi G, Garofoli M. et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis // Curr. Cardiol. Rep. 2012. Vol. 14 (5). P. 601–610.

2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials // Arch Intern Med. 1994. Vol. 154 (13). P. 1449–1457.

3. Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association // Eur. Heart J. 2012. Vol. 33 (21). P. 2719–2747. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24.

4. Connolly S., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial // Lancet. 2006. Vol. 367 (9526). P. 1903–1912.

5. Crijns H.J. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say // Drugs. 2005. Vol. 65 (12). P. 1651–1667.

6. Fang M.C., Go A.S., Chang Y., Borowsky L.H. et al. Warfarin discontinuation after starting warfarin for atrial fibrillation // Circ Cardiovasc Qual Outcomes. 2010. Vol. 3 (6). P. 624–631.

7. Fox C.S., Parise H., D’Agostino R.B.Sr. et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring // JAMA. 2004. Vol. 291. P. 2851–2855.

8. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation // Eur. Heart J. 2010. Vol. 31. P. 967–975.

9. Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266.

10. Goldstein L.B., Akin D.R., Samsa G.P. et al. US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices // Stroke. 1995. Vol. 26 (9). P. 1607–1615.

11. Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins // N. Engl. J. Med. 1998. Vol. 339. P. 659–666.

12. Hart R.G., Halperin J.L. Atrial fibrillation and stroke: Concepts and controversies // Stroke. 2001. Vol. 32. P. 803–808.

13. Hart R.G., Pearce L.A., McBride R. et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators // Stroke. 1999. Vol. 30 (6). P. 1223–1229.

14. Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation // N. Engl. J. Med. 2003. Vol. 349 (11). P. 1019–1026.

15. Jan Heeringa, Deirdre A.M. van der Kuip et al. // European Heart Journal. 2006. Vol. 27. Р. 949–953. doi:10.1093/eurheartj/ehi825.

16. Kirchhof P., Auricchio A., Bax J. Outcome parameters for trials in atrial fibrillation: executive summary // Eur .Heart J. 2007. Vol. 28 (22). P. 2803–2817.

17. Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation // Chest. 2010. Vol. 137 (2). P. 263–272.

18. Lloyd-Jones D.M., Wang T.J., Leip E.P. et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study // Circulation. 2004. Vol. 110 (9). P. 1042–1046. Epub 2004 Aug 16.

19. Mak K-H. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials // BMJ Open. 2012. Vol. 2. e001592.

20. Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.

21. Nieuwlaat R., Capucci A., Camm A.J. et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation // Eur. Heart J. 2005. Vol. 26. P. 2422–2434.

22. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011 Vol. 365(10). P. 883–891.

23. Pisters R., Lane D.A, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey // Chest. 2010. Vol. 138 (5). P. 1093–1100.

24. Stöllberger C., Schneider B., Finsterer J. Elimination of the left atrial appendage to prevent stroke or embolism? // Chest. 2003. Vol. 124 (6). P. 2356–2362.

25. Sun Y., Hu D. The link between diabetes and atrial fibrillation: cause or correlation? // J. Cardiovasc. Dis. 2010. Vol. 1. P. 10–11.

26. Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrilla-tion: a systematic review // Am. J. Med. 2006. Vol. 119 (448). e1–e19.

27. Tonje A. Aksnes and Sverre E. Kjeldsen. A link between hypertension and atrial fibrillation: methods of treatment and prevention // Current Vascular Pharmacology. 2010. Vol. 6. P. 769–774.

28. Vidaillet H., Granada J.F., Chyou P. et al. A population-based study of mortality among patients with atrial fibrillation or flutter // Am. J. Med. 2002. Vol. 113 (5). P. 365-370.

29. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited // Lancet. 2009. Vol. 373. P. 155–166.